Dehghani F, Sezavar Seyedi Jandaghi SH, Janani L, Sarebanhassanabadi M, Emamat H, Vafa M
M.LilleyK
Despite promising preclinical results and its favorable safety profile, BPC 157 lacks FDA approval, necessitating further clinical trials to validate its therapeutic potential and establish comprehensive safety data
Long-term therapy: Designed for ongoing use, not a short-term cycle. Supervision required: As a clinical-stage drug, dosing outside trials is not standardized and should be overseen by medical professionals
This is ridiculous
For example, in experimental arthritis, it has been demonstrated that the systemic administration of ACs protected mice from autoimmune arthritis by inducing regulatory B cells, thereby restraining inflammatory responses [41]